To access this element change to forms mode OFF
Grant Award View - GA276605
Targeting the hepatitis B e antigen as a novel therapeutic approach
GA ID:
GA276605
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Oct-2022
Publish Date:
19-Dec-2022
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2026
Value (AUD):
$1,400,226.80
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Targeting the hepatitis B e antigen as a novel therapeutic approach
Purpose:
There is no cure for chronic hepatitis B virus disease. The secreted hepatitis B e antigen (HBeAg) is a major cause of chronic infection, and its removal by host immune responses improves patient health. Current antiviral therapy does not specifically target this protein. We have developed novel methods to reducing HBeAg levels in a mouse model of HBV persistence. This proposal will progress these findings towards a novel therapeutic approach to treat HBeAg-+ve chronic hepatitis B.
To do..
To do..
GO ID:
GO Title:
Ideas Grants 2022
Internal Reference ID:
2022/GNT2018797
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, VIC, QLD
Postcode:
Multiple
Country:
AUSTRALIA